COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response
The guideline on gastrointestinal and liver conditions provides clinicians with advice on how to adjust care to reduce patients’ exposure to COVID-19 and how to balance the risks and benefits of taking drugs that affect the immune response during the pandemic.
It recommends that patients who are not known to have COVID-19 continue to take existing courses of drugs that affect the immune response to minimise the risk of a flare-up.
If a patient develops COVID-19 symptoms, it’s recommended that they contact their clinical team to get advice about any drugs they are taking.
Clinicians should then discuss the risks and benefits of stopping treatment with the patient or their parents or carers taking into account factors such as the severity of the COVID-19, the severity of their condition and other risk factors such as age and other health conditions.
Read more here: https://www.nice.org.uk/guidance/ng172